Aiming for Upstream Applications and Broader Portfolio, Millipore Plans to Acquire Serologicals | GenomeWeb

In an effort to expand its bioscience offerings and gain a piece of the upstream bioprocessing market, Millipore signed a deal this week to acquire Serologicals for $1.4 billion in cash.

The acquisition will enable Millipore to access new high-growth research markets and will place it in more direct competition with several companies in the BCW Index, including Invitrogen, Qiagen, and Sigma-Aldrich.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.